- Neither compound has a completed human trial for muscle injury. A randomised trial of BPC-157 in acute hamstring injury was registered in 2026 (NCT07437547) and has not reported results.
- In preclinical studies, BPC-157 is linked to new blood vessel growth and fibroblast activity at the injury site. TB-500 is a fragment of thymosin beta-4, which binds actin and is linked to cell migration.
- The human trials often cited for TB-500 used full-length thymosin beta-4 and tested dry eye and venous leg ulcers, not muscle.
- The one published head-to-head, a 2026 preclinical study of Achilles tendon healing, found TB-500 alone outperformed BPC-157 alone, and the two together did not beat TB-500 alone.
- Neither is an approved medicine, neither may be compounded by US pharmacies, and both are prohibited in sport at all times.
BPC-157 and TB-500 are discussed together so often that they are easy to treat as one thing. They are not. They are different molecules with different proposed mechanisms, and the evidence behind each is thinner than the volume of discussion suggests. Neither has a completed human trial for muscle injury. This page sets out what has been tested, in what, and what has not.
Completed human trials of either compound for muscle injury
A randomised trial of BPC-157 in acute hamstring injury was registered in 2026 (NCT07437547). As of October 2026 it has not reported results. TB-500, the fragment, has no registered muscle trial.
This page is education about the research record. It does not recommend using either compound. Neither is an approved medicine.
What preclinical studies link BPC-157 to
BPC-157 is a 15-amino-acid peptide first isolated from gastric juice. Its best-known proposed mechanism is angiogenesis, the growth of new blood vessels into damaged tissue. In preclinical models it activates the VEGFR2 and Akt-eNOS signalling pathways linked to new vessel formation, and FAK-paxillin signalling in fibroblasts, the cells that lay down collagen.
A 2025 narrative review by McGuire et al. in Current Reviews in Musculoskeletal Medicine collected this work and described biomechanical improvements in preclinical injury models beginning around three weeks. The same review was explicit that the human record is limited to small, uncontrolled reports.
What preclinical studies link TB-500 to
TB-500 is a seven-amino-acid fragment of thymosin beta-4, a protein that binds G-actin, one of the building blocks of the cell's internal scaffolding. In preclinical work, thymosin beta-4 is linked to cell migration toward injured tissue and to lower inflammatory signalling.
Two caveats matter when reading claims about it. First, the human trials often cited for TB-500 used the full 43-amino-acid protein and tested severe dry eye and venous leg ulcers, not muscle or tendon injury. Second, a 2024 preclinical study suggested that some of thymosin beta-4's activity may come from a smaller metabolite, Ac-LKKTE, rather than the full peptide. If that holds, the usual explanation of how it works is incomplete.
"Both BPC-157 and thymosin beta-4 offer mechanistically distinct and potentially complementary tissue repair pathways. The primary barrier to clinical adoption remains the absence of controlled human data for either compound."
Rahman OF et al., Journal of the American Academy of Orthopaedic Surgeons, 2026
BPC-157 vs TB-500: the evidence side by side
| Question | BPC-157 | TB-500 |
|---|---|---|
| What it is | 15-amino-acid peptide from gastric juice | 7-amino-acid fragment of thymosin beta-4 |
| Proposed mechanism (preclinical) | New blood vessel growth, fibroblast and collagen activity | Actin binding, cell migration, lower inflammatory signalling |
| Human trials for muscle injury | None completed; one registered (NCT07437547) | None |
| Human trials of any kind | Small safety and uncontrolled reports | Full-length thymosin beta-4 only, for dry eye and venous ulcers |
| FDA status | Not approved | Not approved |
| WADA status | Prohibited at all times (S0) | Prohibited at all times (S2) |
The one head-to-head study
Only one published study has compared the two directly. Bicer et al. (Joint Diseases and Related Surgery, 2026) tested each compound alone and the two together in a preclinical model of Achilles tendon healing, over four weeks. TB-500 alone significantly improved maximum load to failure and tissue scores. BPC-157 alone improved numerically without reaching significance on the total scores. The two together did not beat TB-500 alone.
That is one preclinical study in tendon, not muscle, and it has not been repeated. It is still the only direct comparison, and it does not support the common assumption that the two together add to either one.
The 2025 McGuire review also cites a retrospective case series in knee pain that reported pain relief with the two compounds together. It had no control group, so it cannot separate any effect of the compounds from natural recovery and expectation.
What genetics research says, and does not say
Some gene variants have been linked to soft tissue injury risk in human studies. None has been tested as a predictor of response to either peptide.
COL5A1 helps build type V collagen, which regulates the spacing of larger collagen fibrils in tendon and fascia. A 2025 meta-analysis by Sun et al. in International Journal of Molecular Sciences linked the T allele at rs13946 to higher ACL injury risk (odds ratio 1.34).
NOS3 makes endothelial nitric oxide synthase. The Glu298Asp variant (rs1799983) is associated with lower enzyme activity. It sits on the pathway BPC-157 acts on in preclinical work, which makes it biologically interesting, but no study has tested whether it changes response.
MMP3 encodes an enzyme that breaks down extracellular matrix during repair. Variants such as rs679620 have been associated with soft tissue injury history in athletes.
No study has tested whether any of these genotypes changes response to BPC-157 or TB-500. A DNA report can tell you which versions you carry and what the injury-risk research found; it says nothing about the effect of either compound.
Regulatory and sport status
Neither BPC-157 nor TB-500 is an FDA-approved drug, and neither is on the list of bulk substances US pharmacies may use for compounding. An FDA advisory committee discussed BPC-157 in July 2026, but an advisory vote does not change that list; only FDA can. FDA treats products containing them as unapproved drugs when they are marketed for people.
Both are prohibited by WADA at all times, in and out of competition: BPC-157 under S0 (non-approved substances) and TB-500 under S2 (growth factors and related substances).
Verdict: the honest comparison is between two sets of preclinical findings. BPC-157 has the larger preclinical literature and one registered human muscle trial with no results yet. TB-500 has no muscle trial, and its human data belongs to a different molecule. The only direct comparison, a single preclinical tendon study, favoured TB-500 alone and found no added benefit when the two were tested together.
BPC-157
The most studied research peptide for tissue repair, and almost none of it in people
Watch
What clinicians and researchers say about BPC-157
20 minExposing The Truth About PeptidesDoctor Mike · ClinicianBPC-157TB-500KPV
1 hr 30 minPeptide Expert: What Do Peptides Actually Do? (EXPLAINED) - Dr Alex TatemThe Diary of a CEO · PodcastBPC-157TB-500MOTS-c
15 minAndrew Huberman's Longevity Routine (supplements, diet, peptides, and exercise regimen)Rhonda Patrick · ResearcherBPC-157SermorelinFrequently asked questions
Has BPC-157 or TB-500 been tested in people for muscle injury?
Not in a completed trial. A randomised trial of BPC-157 in acute hamstring injury was registered in 2026 (NCT07437547) and had not reported results as of October 2026. TB-500 has no registered muscle trial. The evidence for both in muscle injury is preclinical.
How do BPC-157 and TB-500 differ?
They are different molecules with different proposed mechanisms. In preclinical work, BPC-157 is linked to new blood vessel growth and fibroblast activity at the injury site. TB-500 is a fragment of thymosin beta-4, a protein that binds actin and is linked to cell migration. Neither mechanism has been confirmed in human muscle injury.
Did research find the two together outperformed either alone?
No. The only published head-to-head, a 2026 preclinical study of Achilles tendon healing by Bicer et al., found TB-500 alone outperformed BPC-157 alone, and the two together did not beat TB-500 alone. No human comparison exists.
Is TB-500 the same as thymosin beta-4?
No. TB-500 is a seven-amino-acid fragment; thymosin beta-4 is the full 43-amino-acid protein. The human trials often cited for TB-500 used the full protein and tested severe dry eye and venous leg ulcers, not muscle or tendon injury.
Are BPC-157 and TB-500 approved or legal to compound in the US?
Neither is an FDA-approved drug, and neither is on the list of bulk substances US pharmacies may compound. An FDA advisory committee discussed BPC-157 in July 2026, but only FDA can change the list. Both are prohibited by WADA at all times.
Can genetics predict whether BPC-157 or TB-500 will work?
No study has tested that. Variants in COL5A1, NOS3 and MMP3 have been linked to soft tissue injury risk in human studies, but none has been tested as a predictor of response to either peptide.
This article is for informational and educational purposes only. It reports what published research found; it is not medical advice, it does not diagnose, treat, cure or prevent any disease, and nothing in it is a dose or a recommendation to use any compound. Talk to a licensed clinician about any medical decision.